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LETTERS TO THE EDITOR 
Beta-Endorphin in Congestive Heart Failure 
In their recent article, Kawashima et al. (I) suggest that "a study 
using an opioid receptor antagonist should be conducted to clarify 
the causal role of beta-endorphin for the hypoperfusion in heart 
failure." In such a study, we (2) found that naloxone, in doses of up 
to 1.0 mg/kg had no effect on rest hemodynamics in patients with 
chronic, stable but severe congestive heart failure. The study of 
Kawashima et al. is another example of an epiphenomenon that is 
probably of little significance in the overall pathophysiology of 
congestive heart failure. I hope that this report does not inspire a 
rash of therapeutic misadventures by misguided physicians working 
on ill-founded assumptions. 
L. ALLEN KINDMAN, MD, FACC 
Cardiology Division 
Falk Cardiovascular Research Center 
Stanford University School of Medicine 
3()() Pasteur Drive 
Stanford, California 94305-5246 
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Reply 
The letter of Kindman appears to be an overreaction in regard to one 
aspect of our report, The main purpose of our study was to show 
elevated plasma beta-endorphin levels in patients with congestive 
heart failure which reflect, to some extent, the severity of the 
disease, As mentioned in the Discussion, our purpose was not to 
clarify the pathophysiologic role of beta-endorphin in congestive 
heart failure. Actually, plasma beta-endorphin levels did not corre-
late with any parameters of left ventricular function, including 
ventricular contractility. Thus, elevated endorphin levels do not 
playa major role in the control of ventricular function. 
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The study of Kindman and Fowler has provided some clarifica-
tion in the understanding of the opioid system in congestive heart 
failure. They observed unchanged systemic hemodynamics after 
naloxone in six patients with severe congestive heart failure. Their 
patients were candidates for orthotopic cardiac transplantation with 
a mean ejection fraction of 11.3 ± 4.4%, who seems to be resistant 
to conventional therapy. From their study it would appear that 
naloxone has been confirmed as ineffective as a therapeutic strategy 
for severe refractory heart failure. Their study, however, cannot 
negate the pathophysiologic role of beta-endorphin in congestive 
heart failure. Their patients were in a very severe condition, fully 
medicated by digoxin, diuretics and captopril and the role of opioids 
might have been masked under such a condition. The redistribution 
of regional blood flow may have occurred after naloxone despite 
unchanged cardiac output (I), Sakamoto et al. (2) indicate the role of 
the opioid system to be involved in the pathogenesis of depressed 
baroreflex function in congestive heart failure. In addition, a recent 
study of Davies et al. (3) suggested that opioid mechanisms modu-
late the perception of dyspnea in chronic heart failure. 
We do not think that one single neurohormonal factor plays a 
major role in the pathophysiology of congestive heart failure. We 
believe that further studies are needed to clarify the role of beta-
endorphin in the pathophysiology of congestive heart failure. 
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